Department of Human Genetics, Sidra Medicine Doha, Doha, Qatar.
Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
Viruses. 2021 Mar 24;13(4):540. doi: 10.3390/v13040540.
Human parvovirus (B19V) is the causative agent of erythema infectiosum in children and is linked to a wide range of clinical manifestations. Studies related to B19V prevalence in the Middle East and North Africa (MENA) region and other parts of Asia are very scarce. The objectives of this study were to estimate the seroprevalence (anti-B19V IgM and IgG), the viremia rate (B19V DNA), and the circulating genotypes of B19V among blood donors in Qatar.
Donors' blood samples ( = 5026) from different nationalities, mainly from the MENA region and South East Asia, were collected from 2014-2016. Samples were tested for the B19V DNA using RT-PCR. Furthermore, 1000 selected samples were tested to determine the seroprevalence of B19V antibodies using enzyme-linked immunosorbent assay (ELISA). Genotyping was performed on 65 DNA positive samples by sequencing of nested PCR fragments (NS1-VP1u region, 927 nt).
Only 1.4% (70/5026) of the samples had detectible B19V DNA in their blood. B19V DNA prevalence statistically decreased with age ( = 0.03). Anti-B19V IgG was detected in 60.3% (561/930) of the tested samples, while only 2.1% (20/930) were IgM-positive and 1.2% (11/930) were both IgM- and IgG-positive. B19V genotyping showed a predominance of Genotype 1 (100%). Sequence analysis of the NS1-VP1u region revealed 139 mutation sites, some of which were amino acid substitutions.
Our results indicated a relatively high seroprevalence of B19V in Qatar. Most importantly, B19 DNA was detected among Qatari and non-Qatari blood donors. Therefore, blood banks in Qatar might need to consider screening for B19V, especially when transfusion is intended for high-risk populations, including immunocompromised patients.
评估卡塔尔献血者中人类细小病毒（B19V）的血清流行率（抗-B19V IgM 和 IgG）、病毒血症率（B19V DNA）和循环基因型。
2014 年至 2016 年，从不同国籍的献血者（=5026 名）中采集血样，主要来自中东和北非（MENA）地区和东南亚。使用 RT-PCR 检测 B19V DNA。此外，对 1000 份选定的样本进行 B19V 抗体酶联免疫吸附试验（ELISA）检测，以确定血清流行率。对 65 份 DNA 阳性样本进行测序，对嵌套 PCR 片段（NS1-VP1u 区，927nt）进行基因分型。
只有 1.4%（70/5026）的样本血液中可检测到 B19V DNA。B19V DNA 流行率随年龄呈统计学下降趋势（=0.03）。在检测的样本中，60.3%（561/930）检测到抗-B19V IgG，而只有 2.1%（20/930）IgM 阳性，1.2%（11/930）同时 IgM 和 IgG 阳性。B19V 基因分型显示 1 型（100%）占主导地位。NS1-VP1u 区序列分析显示有 139 个突变位点，其中一些为氨基酸取代。
我们的结果表明，卡塔尔 B19V 的血清流行率相对较高。最重要的是，在卡塔尔和非卡塔尔献血者中检测到了 B19 DNA。因此，卡塔尔的血库可能需要考虑对 B19V 进行筛查，特别是当输血对象为高危人群，包括免疫功能低下的患者时。
